Company Overview

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and nutrition markets in Switzerland and internationally. It operates through Biologics, Small Molecules, Cell and Gene, and Capsules and Health Ingredients divisions. The Biologics division engages in the contract development and manufacturing services for biopharmaceuticals. The Small Molecules division operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. The Cell and Gene division develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules and Health Ingredients division offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

  • Name

    Lonza Group AG

  • CEO

    Dr. Wolfgang Wienand Ph.D.

  • Website

    www.lonza.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1897

Profile

  • Market Cap

    CHF 38.73B

  • EV

    CHF 40.57B

  • Shares Out

    72.23M

  • Revenue

    CHF 6,696M

  • Employees

    17,834

Margins

  • Gross

    36.01%

  • EBITDA

    27.48%

  • Operating

    19.74%

  • Pre-Tax

    10.44%

  • Net

    8.56%

  • FCF

    0.28%

Returns (5Yr Avg)

  • ROA

    8.05%

  • ROTA

    18.84%

  • ROE

    15.03%

  • ROCE

    8.34%

  • ROIC

    6.9%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    CHF 623.67

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    CHF 2,017M

  • Net Debt

    CHF 1,778M

  • Debt/Equity

    0.4

  • EBIT/Interest

    6.74

Growth (CAGR)

  • Rev 3Yr

    11.68%

  • Rev 5Yr

    3.19%

  • Rev 10Yr

    6.28%

  • Dil EPS 3Yr

    -5.95%

  • Dil EPS 5Yr

    5.35%

  • Dil EPS 10Yr

    8.34%

  • Rev Fwd 2Yr

    6.92%

  • EBITDA Fwd 2Yr

    4.34%

  • EPS Fwd 2Yr

    16.19%

  • EPS LT Growth Est

    16.44%

Dividends

  • Yield

  • Payout

    50.48%

  • DPS

    CHF 4

  • DPS Growth 3Yr

    10.06%

  • DPS Growth 5Yr

    7.78%

  • DPS Growth 10Yr

    6.41%

  • DPS Growth Fwd 2Yr

    15.45%

SWX:LONN